STRIDES PHARMA, INC. – Trademark Portfolio

Entity Type: 03

STRIDES PHARMA, INC. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. Currently, 5 trademarks are registered. Notable registered marks include FERGON, ACCOLATE, VANQUISH, JOINTFLEX, and NITE THRU. The owner is based in EAST BRUNSWICK, NJ.

2 TOWER CENTER BLVD., SUITE 1102

EAST BRUNSWICK, NJ 08816

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

NITE THRU
NITE THRU
Registered 2016
JOINTFLEX
JOINTFLEX
Registered 2010
ACCOLATE
ACCOLATE
Registered 1992
VANQUISH
VANQUISH
Registered 1963
FERGON
FERGON
Registered 1942

Trademark Classifications

STRIDES PHARMA, INC.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does STRIDES PHARMA, INC. have?

STRIDES PHARMA, INC. has 6 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 cancelled.

What trademark classes does STRIDES PHARMA, INC. file in?

STRIDES PHARMA, INC. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are STRIDES PHARMA, INC.'s most well-known trademarks?

STRIDES PHARMA, INC.'s registered trademark portfolio includes well-known marks such as FERGON, ACCOLATE, VANQUISH, JOINTFLEX, and NITE THRU. These are among 5 currently registered trademarks in the portfolio.

What is STRIDES PHARMA, INC.'s trademark registration success rate?

STRIDES PHARMA, INC. has a 83% trademark registration rate, with 5 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.